Skip to main content
Caplight Logo









KiraGen Bio

KiraGen Bio

Private
MassachusettsHealthcare & Life Scienceshttps://www.kiragenbio.com/

Last Round

Grant

Dec 31, 2025

Total Funding Raised

$1.45M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

KiraGen Bio is a biotechnology company that develops multiplex gene-edited CAR-T cell therapies designed to overcome the immunosuppressive tumor microenvironment in solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

CAR-T cell therapymultiplex gene editingAI drug discoverysolid tumor therapycell therapyglioblastoma treatmenttumor microenvironmentTMEoff-the-shelf cell therapyallogeneic cell therapyAI bioprecision medicinebiotech startupgene editing platformsynthetic biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

KiraGen Bio Comparables

Compare KiraGen Bio with similar companies based on industry and business-model similarity.

KiraGen Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Outpace Bio
78%
ArsenalBio
77%
BrainChild Bio, Inc.
77%

KiraGen Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 31, 2025
AcceleratorApr 23, 2025
Pre SeedApr 1, 2025

Key People

Founding team and executive leadership

Ryan Murray

Co-Founder Chief Scientific Officer

Founding Team

Aaron Edwards

Co-Founder CEO

Founding Team

KiraGen Bio Investors

Notable investors and investment history

KiraGen Bio investors
InvestorRounds
Lexi VenturesPre Seed
Harvard Innovation LabsPre Seed
GaingelsPre Seed
Yuvaan Tiwari FoundationPre Seed
ZAKA VCPre Seed
Conscience VCPre Seed
2048 VenturesPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 31, 2025

    Secured $50K in grant funding.

  • Jul 12, 2025

    Featured on The Sheekey Science Show.

KiraGen Bio Filings

Explore SEC and related filing metadata, where available.

KiraGen Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about KiraGen Bio's valuation, stock price, and market status.

Is KiraGen Bio a public or private company?

KiraGen Bio is a private company.

What is the current stock price of KiraGen Bio?

KiraGen Bio is a private company, so its shares have no public market price. Caplight tracks KiraGen Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is KiraGen Bio worth (valuation)?

Valuation information for KiraGen Bio is not publicly available.

Can I buy KiraGen Bio stock?

KiraGen Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was KiraGen Bio's last funding round?

KiraGen Bio's most recent funding round was Grant on December 31, 2025.

Who are the main investors in KiraGen Bio?

Key investors in KiraGen Bio include ZAKA VC, Conscience VC, 2048 Ventures.

Will KiraGen Bio IPO soon?

No public IPO plans have been announced for KiraGen Bio.

How can I track KiraGen Bio secondary market activity?

Caplight tracks bids, offers, and trades in KiraGen Bio's shares on secondary markets.

Firmographic Details

HeadquartersMassachusetts
Employee Range5
Year Founded2023
Last FundingDec 31, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?